牛牛AI助理已提取核心訊息
On March 4, 2024, Frazier Life Sciences VIII, L.P., along with associated entities and individuals, filed an amendment to their Schedule 13D with the SEC, disclosing their ownership stake in Arcutis Biotherapeutics, Inc. The filing indicates that Frazier Life Sciences VIII, L.P. and its general partner entities, as well as James N. Topper and Patrick J. Heron, collectively hold 8,785,284 shares of common stock, representing a 7.8% ownership in the company. The shares are held for investment purposes, and the group may acquire additional shares or dispose of their holdings depending on market conditions and their ongoing evaluation of the business. The filing also details the history of their investment in Arcutis, including purchases of common and preferred stock, and distributions to partners. Additionally, the filing outlines certain agreements, including a lock-up agreement restricting the sale of shares until April 28, 2024, and an Investors' Rights Agreement that allows for registration of shares for resale under certain conditions.
On March 4, 2024, Frazier Life Sciences VIII, L.P., along with associated entities and individuals, filed an amendment to their Schedule 13D with the SEC, disclosing their ownership stake in Arcutis Biotherapeutics, Inc. The filing indicates that Frazier Life Sciences VIII, L.P. and its general partner entities, as well as James N. Topper and Patrick J. Heron, collectively hold 8,785,284 shares of common stock, representing a 7.8% ownership in the company. The shares are held for investment purposes, and the group may acquire additional shares or dispose of their holdings depending on market conditions and their ongoing evaluation of the business. The filing also details the history of their investment in Arcutis, including purchases of common and preferred stock, and distributions to partners. Additionally, the filing outlines certain agreements, including a lock-up agreement restricting the sale of shares until April 28, 2024, and an Investors' Rights Agreement that allows for registration of shares for resale under certain conditions.
2024年3月4日，弗雷澤生命科學VIII, L.P. 及其關聯實體和個人向美國證券交易委員會提交了附表13D修正案，披露了其在Arcutis Biotherapeutics, Inc.的所有權。該文件顯示，弗雷澤生命科學八有限責任公司及其普通合夥實體以及詹姆斯·託珀和帕特里克·赫倫共持有8,785,284股普通股，佔該公司7.8％的所有權。持有這些股份是出於投資目的，根據市場狀況及其對業務的持續評估，集團可能會收購更多股份或處置其持有的股份。該文件還詳細介紹了他們在Arcutis的投資歷史，包括購買普通股和優先股以及向合作伙伴分配。此外，該文件還概述了某些協議，包括限制在2024年4月28日之前出售股票的封鎖協議，以及允許在某些條件下注冊股票進行轉售的投資者權利協議。
2024年3月4日，弗雷澤生命科學VIII, L.P. 及其關聯實體和個人向美國證券交易委員會提交了附表13D修正案，披露了其在Arcutis Biotherapeutics, Inc.的所有權。該文件顯示，弗雷澤生命科學八有限責任公司及其普通合夥實體以及詹姆斯·託珀和帕特里克·赫倫共持有8,785,284股普通股，佔該公司7.8％的所有權。持有這些股份是出於投資目的，根據市場狀況及其對業務的持續評估，集團可能會收購更多股份或處置其持有的股份。該文件還詳細介紹了他們在Arcutis的投資歷史，包括購買普通股和優先股以及向合作伙伴分配。此外，該文件還概述了某些協議，包括限制在2024年4月28日之前出售股票的封鎖協議，以及允許在某些條件下注冊股票進行轉售的投資者權利協議。
有用
沒用